SLS Stock Price, Chart, Stats & News
SELLAS Life Sciences Group, Inc. (SLS) does not currently pay a dividend.
SLS chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -34.29% |
ROE | -63.06% |
D/E | 0.01x |
Interest coverage ratio | – |
SLS valuation
P/E | – |
P/S | – |
P/B | 9.43x |
P/CF | -23.54x |
P/FCF | -21.90x |
P/OCF | -23.54x |
PEG | -1.80x |
EV multiple | -33.58x |
About
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology.
Similar securities
Based on sector and market capitalization
